Drug news
Amylin acquires world rights to Byetta and Bydureon for Type 2 Diabetes from Eli Lilly
Amylin and Eli Lilly have agreed to revise their collaboration concerning the Type 2 Diabetes therapies ,Byetta (exenatide injection) and Bydureon (exenatide extended release, being the weekly version),as a result of Eli Lilly entering a collaboration with Boehringer for competitor Tradjenta (linagliptin).Amylin will acquire all the rights to Byetta and Bydureon and pay royalties to Eli Lilly. Court proceedings will be withdrawn.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.